Treatments being tested
Clinical trials open to people with bowel cancer
Every trial here is a live record from ClinicalTrials.gov, the public registry every trial must be listed on before it starts. Statuses are re-checked against the registry every day or two, because a list that says a closed trial is recruiting is worse than no list at all.
Listing a trial is not a recommendation, and this site has no connection to any of them. Whether a trial is right for you, and whether you would be eligible, is a conversation for your own oncology team.
What these filters mean
Genotype
These are the things that make a tumour unusual, so leave them alone unless one of them is yours. Nothing selected shows every trial. Wild-type and pMMR are the ordinary results and have no button of their own: they would match almost everybody, so they would narrow nothing. Selecting a mutation drops the trials that need the ordinary result instead â which is right, because those are the ones you could not join.
Which KRAS
Only relevant if your tumour is KRAS mutated. Your report will name the exact change, such as G12C or G12D; some newer drugs are built for one specific change and no other.
Each trial is tagged by reading its own eligibility criteria automatically, to make the list searchable. The tags summarise what the criteria mention — they are not a decision about whether you qualify, and where a tag and the criteria disagree, the criteria are right.
403 trials
Recruiting nowPhase 2
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Recruiting nowPhase 2
Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer
Recruiting nowPhase 2
Evaluation of XYA02 in Patients With Advanced Solid Tumors
Recruiting nowPhase 2
Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC
Recruiting nowPhase 2
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Recruiting nowPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Recruiting nowPhase 1
A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
Recruiting nowPhase 2
SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET
Recruiting nowPhase 2
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Recruiting nowPhase 2
Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression
Recruiting nowPhase 2
A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
Recruiting nowPhase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
Recruiting nowPhase 2
Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
Recruiting nowPhase 2
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
Recruiting nowNot phased
Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node